演題抄録

臓器別シンポジウム

開催概要
開催回
第56回・2018年・横浜
 

肺がん脳転移に対する全身薬物療法

演題番号 : SY16-3

[筆頭演者]
演者)村上 晴泰:1 

1:静岡県立静岡がんセンター・呼吸器内科

 

Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC), and the development of BM is associated with poor prognosis and has an adverse impact on quality of life. Because of limited specific treatment options, there is a real need for the development of effective treatment strategy for patients with NSCLC and BM.
Genomic characterization of lung tumors and matched targeted therapies such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (e.g. gefitinib, erlotinib, afatinib, dacomitinib and osimertinib) and anaplastic lymphoma kinase (ALK) TKIs (e.g. crizotinib, ceritinib and alectinib) have been developed actively and have contributed to improved outcomes of advanced NSCLC treatment. These new treatment options have led to profound clinical benefit for patients, both in preventing or delaying the onset of BM, and in leading to intracranial remissions for patients with preexisting lesions. Recently, anti-programmed death-1 (PD-1) and anti-PD-ligand 1 (PD-L1) immune checkpoint-inhibitors also demonstrate survival benefit in patients with NSCLC, and several drugs (e.g. nivolumab, pembrolizumab, atezolizumab and durvalumab) have been approved in Japan. Recent advances in systemic drug therapy of NSCLC have generated considerable interest in exploration of those therapies for treatment of intracranial metastases. I will review recent clinical investigations that highlight the effects of molecular targeted drugs targeting EGFR, ALK and other receptor oncogenes, as well as the promise of immunotherapy in NSCLC central nervous system disease, and discuss the future direction of treatment paradigm for patients with NSCLC and BM.

前へ戻る